Abstract:: Alzheimer's disease (AD) is a degenerative disease of the nervous system. Mainly presenting with neuropsychiatric symptoms such as progressive memory impairment, cognitive dysfunction, personality changes, and language disorders [1] . Also known as senile dementia, it is the leading cause of dementia in the elderly [2] . Involved in 60-80% of all reports of dementia [3] . As the global population ages, AD prevalence and mortality rates increase. It seriously affects the quality of life of the elderly and brings a heavy economic burden and severe social problems. The tea polyphenol epigallocatechin gallate (EGCG) has preventive and therapeutic effects on Alzheimer's disease by inhibiting the amyloid formation and aggregation, antioxidant, anti-inflammatory, metal chelating, binding cholinesterase, thereby reducing the degradation of acetylcholine, and repairing mitochondrial dysfunction. This article reviews the research on the mechanism of EGCG action on Alzheimer's disease. necrosis and brain tissue damage have higher concentrations of Cu2 Zn2 +, and Fe3+ in the brain [50] , and EGCG has complexation for both Cu2 + and Fe3+ [51] The chelation of iron by EGCG interferes with iron-induced degradation and inactivation of iron regulatory protein (IRP1/2), leading to a decrease in amyloid precursor protein (APP) [52] It has been observed in electrochemistry and optics that EGCG inhibits the formation of Cu2+His complex by acting on Cu2+, thus reducing the formation of fiber [53] . EGCG also showed the ability to inhibit trivalent aluminum ion-induced Aβ42 fibrillation and significantly reduced Aβ42 toxicity by preventing further folding of Aβ42 monomers [54] . EGCG not only chelates free metal ions but also regulates the aggregation of Aβ after metal binding. In the effect of EGCG-bound metal ions on the structure of Aβ, it was found that the addition of EGCG to Cu 2+, Zn 2+ -bound Aβ generates free state Aβ aggregates, while structural Aβ aggregates are generated in metal-bound Aβ without the addition of EGCG [55] . These findings suggest that EGCG can compete with Aβ to bind metal ions, reduce APP production, prevent Aβ aggregation, and continue to inhibit Aβ aggregate binding after Aβ binding metal ions, thus preventing Aβ deposition and neurotoxicity.

Inhibition of Aβ Aggregates in Alzheimer’s Disease by Epigallocatechin and Epicatechin-3-gallate from Green Tea

Epigallocatechin-3-Gallate Provides Protection Against Alzheimer's Disease-Induced Learning and Memory Impairments in Rats

Alzheimer's Disease and Green Tea: Epigallocatechin-3-Gallate as a Modulator of Inflammation and Oxidative Stress

Green Tea Extracts EGCG and EGC Display Distinct Mechanisms in Disrupting Aβ42 Protofibril.

Multifaceted neuroprotective effects of (-)-epigallocatechin-3-gallate (EGCG) in Alzheimer’s disease: an overview of pre-clinical studies focused on β-amyloid peptide

Green Tea Suppresses Amyloid β Levels and Alleviates Cognitive Impairment by Inhibiting APP Cleavage and Preventing Neurotoxicity in 5XFAD Mice

Green tea extract EGCG plays a dual role in Aβ42 protofibril disruption and membrane protection: A molecular dynamic study.

Association of Tea Consumption with Risk of Alzheimer's Disease and Anti-Beta-Amyloid Effects of Tea

Molecular Insights into the Inhibition and Disaggregation Effects of EGCG on Aβ40 and Aβ42 Cofibrillation

Research progress of EGCG in the treatment of Alzheimer's disease

Progress in the Prevention of Tea Polyphenols on Alzheimer's Disease and Their Mechanisms

Understanding the mechanisms of green tea EGCG against amyloid β oligomer neurotoxicity through computational studies

Comparative Kinetics of Acetyl- and Butyryl-Cholinesterase Inhibition by Green Tea Catechins|Relevance to the Symptomatic Treatment of Alzheimer’s Disease

Neuroprotective Effects and Mechanisms of Tea Bioactive Components in Neurodegenerative Diseases

Protective Effects of Green Tea and Green Tea Polyphenols on Alzheimer's Disease

The efficacy of Epigallocatechin-3-gallate (green tea) in the treatment of Alzheimer’s disease: an overview of pre-clinical studies and translational perspectives in clinical practice

Inhibition Mechanisms of (-)-epigallocatechin-3-gallate and Genistein on Amyloid-beta 42 Peptide of Alzheimer's Disease Via Molecular Simulations

The Inhibition Effect of Epigallocatechin-3-Gallate on the Co-Aggregation of Amyloid-β and Human Islet Amyloid Polypeptide Revealed by Replica Exchange Molecular Dynamics Simulations

The pharmacological activity of epigallocatechin-3-gallate (EGCG) on Alzheimer's disease animal model: A systematic review

Epigallocatechin-3-gallate Inhibits LPS/AβO-induced Neuroinflammation in BV2 Cells through Regulating the ROS/TXNIP/NLRP3 Pathway

Neurodegenerative diseases and catechins: (-)-epigallocatechin-3-gallate is a modulator of chronic neuroinflammation and oxidative stress